Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA, EMA accept AstraZeneca Vandetanib for review
The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011. The
The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011. The
Medtronic said that the findings include one-year results for Resolute International, two subsets from Resolute All Comers, and four-year results for the Resolute feasibility study, which supported the
The Apposition II trial involved 80 patients and was conducted in 6 European countries, between December 2009 and June 2010, which compares the Stentys self-apposing stent with a
The collaboration will explore the use of EyeGate’s iontophoresis technology, which is currently being studied in a Phase III trial with an anti-inflammatory product (EGP-437), to deliver RXi’s
Parexel will assist Lilly in bringing efficiencies to its clinical research studies to help meet Lilly’s development and commercialisation goals. The collaboration will allow Lilly to focus on
As per the terms of the agreement, Sanofi-aventis will have access to Belfer’s cancer target identification and validation platform, and translational medicine capabilities. Belfer has licensed Sanofi-aventis an
Mitsui has been a solution provider to pharma firms with services ranging from supplying raw materials, chemical intermediates and APIs to support management of manufacturing as well as
Roche claims that its new test provides a fully automated solution for the quantitative detection of hepatitis B virus (HBV) DNA in human plasma or serum for patients
The Detect-Ready MRSA kit is a qualitative real-time PCR (rt-PCR) in-vitro diagnostic test for the direct detection of MRSA nasal colonization to aid in the prevention and control
Based on HemCon’s proprietary oxidised cellulose platform, Synaero Hemostatic Gel is a hemostatic gel to be used during and after ENT surgical procedures to control bleeding, minimise edema